Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Yabumoto

Cardiovascular Disease Alhambra, CA Medical Doctor

NPI 1730383522 CMS profile 1096230

220 S 1St St, Alhambra, CA 91801

Open in the dashboard

General payments

$7,901

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith Yabumoto of Alhambra, CA is reported in the CMS Open Payments database as having received $7,901 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $869 17
2024 General $772 27
2023 General $878 16
2022 General $751 38
2021 General $1,191 35
2020 General $1,290 25
2019 General $2,151 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Yabumoto
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Keith Yabumoto were reported at $869. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Keith Yabumoto Cardiovascular Disease median Middle half National median
2019 $2,151 $450 $127–$1,392 $163
2020 $1,290 $242 $77–$751 $114
2021 $1,191 $335 $101–$1,037 $132
2022 $751 $395 $121–$1,211 $149
2023 $878 $443 $136–$1,283 $160
2024 $772 $450 $136–$1,323 $164
2025 $869 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $1,732 24 payments
  2. Medtronic, Inc. $1,723 18 payments
  3. E.R. Squibb & Sons, L.L.C. $883 66 payments
  4. Boston Scientific Corporation $867 12 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $712 17 payments
  6. Abbott Laboratories $392 6 payments
  7. Pfizer Inc. $391 18 payments
  8. Amgen Inc. $324 14 payments
  9. Janssen Pharmaceuticals, Inc $206 9 payments
  10. Kestra Medical Technology Services, Inc. $142 1 payment
  11. Other $529 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,881 208 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. Reveal LINQ Cardiac Diagnostics and Monitoring $1,114 18 payments
  2. Micra $700 6 payments
  3. ELIQUIS Cardiovascular $680 55 payments
  4. JARDIANCE Diabetes $491 5 payments
  5. LINQ II $401 6 payments
  6. CoreValve Evolut $365 3 payments
  7. ELIQUIS Cardiovascular;Metabolic Disease $320 14 payments
  8. Reveal LINQ Cardiac Diagnostics and Monitoring $304 4 payments
  9. Repatha $278 10 payments
  10. JARDIANCE Diabetes $221 12 payments
  11. Other $3,206 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,197

Median for Cardiology: 2,533

Drug cost

$928,985

Median for Cardiology: $485,213

Branded share of claims

37.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 420 $436,375
Vyndamax Tafamidis Brand 13 $296,122
Repatha Sureclick Evolocumab Brand 75 $59,358
Xarelto Rivaroxaban Brand 39 $41,962
Jardiance Empagliflozin Brand 14 $23,475
Entresto Sacubitril/Valsartan Brand 17 $23,329
Propafenone Hcl Er Propafenone Hcl Brand 35 $15,204
Edarbi Azilsartan Medoxomil Brand 19 $6,448
Valsartan Generic 144 $4,256
Ranolazine Er Ranolazine Brand 19 $2,559

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$243,669

Medicare's payments for the services billed

Medicare patients

904

Average age 78

Services billed

3,154

474 women, 430 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 50%
Diabetes 43%
Heart failure 41%
Atrial fibrillation 39%
Chronic kidney disease 38%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $202
$202 14 —
XARELTO
  • Janssen Pharmaceuticals, Inc $69
$69 39 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $55
$55 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $36
$36 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $21
$21 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record